Page 2425 - Williams Hematology ( PDFDrive )

2396 Index Index 2397

ADAMTS-13 (ADAMTS13) (Cont.): neutrophil, 934t, 1006 definition, history, and epidemiology,
in disseminated intravascular coagulation, in thrombotic milieu, 1978, 1979t 2134t, 2154
2207 Adipocytes, marrow, 59, 59f differential diagnosis, 2156
in liver disease, 2191, 2193 Adiponectin, in myeloma, 1709 etiology and pathogenesis, 2154–2155
preeclampsia and, 2012 Adipose tissue laboratory features, 2155–2156
in thrombotic microangiopathies, 1252 eosinophils and, 952 in pregnancy, 2156
in thrombotic thrombocytopenia purpura, hematopoiesis and, 44 therapy, 2136t, 2156–2157
428, 2107, 2253–2255 macrophage phenotypes in, 1078 African Americans
von Willebrand factor and, 1874, 1879, Adoptive cellular therapy. See Immune cell cardiac amyloidosis and, 1778
1979, 2012, 2167, 2167f, 2254f therapy monoclonal gammopathy and, 1722
Adaptive immunity Adoptive immune therapy, 353 myeloma and, 1734
activation, 303–304 ADP (δ-aminolevulinate dehydratase sickle cell disease and, 763
atherosclerosis and, 2286 porphyria), 890t, 891f, 891t, 894, African iron overload, 640, 641, 643
dendritic cells and, 307–308, 308t 900 Age
vs. innate immunity, 293, 294t ADP (adenosine diphosphate) acute lymphoblastic leukemia incidence
natural killer cells and, 1191 activation of Akt by, 1882 and, 1506, 1506f
Adaptive tolerance, 308 in glucose metabolism, 692 acute lymphoblastic leukemia prognosis
Adaptor proteins, 251–252, 1833t oxidation of red cells with, 499 and, 1520–1521, 1521t
ADCC (antibody-dependent cellular platelet response to, 2074 chronic myelogenous leukemia incidence
cytotoxicity), 344–345, 1645 receptors for, 1874–1876 and, 1438, 1439f
Addison disease, 559–560 ADP receptor blockers, 405, 2076 endothelial vasodilation and, 2283
Adducins, 663t, 667, 668f, 1833t, 1837, ADP receptor defects (P2Y and P2X ), hairy cell leukemia incidence and, 1554
1
12
1840 2056–2057 hematopoietic cell transplantation and,
Adenine nucleotides, metabolic and storage Adrenal disease/dysfunction 361–362
pools of, 1843 anemia and, 559–560 Hodgkin lymphoma incidence and, 1604,
Adenine phosphoribosyl transferase, 701t in antiphospholipid syndrome, 2241 1604f
Adeno-associated viral (AAV) vectors, in disseminated intravascular coagulation, immune function and, 135–136, 136f
438–439, 442, 2129 2205t leukocyte count and, 17
Adenosine deaminase (ADA), 692t, 699, primary lymphomas, 1583 lymphoma incidence and, 1570, 1570f
700t, 701t, 705–706 Adrenoleukodystrophy, X-linked, 439 mononucleosis symptoms and, 1263t
Adenosine deaminase (ADA) deficiency, 439, Adriamycin. See also ABVD regimen; myelodysplastic syndrome incidence and,
1214t, 1217, 1218 BEACOPP regimen 1344, 1344f
Adenosine diphosphate. See ADP (adenosine for acute lymphoblastic leukemia, 1516 neutrophil concentration and, 991
diphosphate) Adult Langerhans cell histiocytosis, primary myelofibrosis incidence and, 1319
Adenosine monophosphate kinase (AMPK), 1108–1109. See also Langerhans reference ranges and, 19
194–195 cell histiocytosis Agent Orange, 1528
Adenosine signaling, in sickle cell disease, Adult T-cell leukemia/lymphoma (ATL/ Agglutinins, direct (saline), 823
765–766 ATLL) Aggressive systemic mastocytosis, 973. See
Adenosine triphosphate. See ATP (adenosine chromosomal abnormalities, 185t, 186f also Systemic mastocytosis
triphosphate) clinical features, 1700 AGI-6780, 1403
Adenosylcobalamin, 589, 589f, 592, 592f definition, 1700 Aging. See also Newborns/infants; Older
Adenoviral vectors, 438 epidemiology, 1573, 1694t, 1700 persons
Adenovirus infection. See also Viral laboratory features, 1498t, 1700 acute myelogenous leukemia and, 1375,
infections prognosis, 1700–1701 1375f, 1412, 1412t
in immunocompromised host, 384 treatment, 1701 cellular senescence, 132
T-cell therapy for, 412 Adventitial reticular cells, marrow, 57–59, hematopoietic microenvironment and, 267
Adenylate kinase (AK), 692t, 699, 700t, 705 57f, 58f median life span vs. maximum survival,
Adenylate kinase 2 deficiency, 1217 AE1 (anion exchanger), 663t, 664 131
Adhesion molecules Aes-103, for sickle cell disease, 777t neutrophil motility and, 1026
atherosclerosis and, 2286 AF4 proteins, 169 organismal, 132
in cell signaling, 250 AF9 proteins, 169 theories, 130–131, 130t
eosinophil, 948–949, 949t Afamelanotide, for erythropoietic AGM (aorta-gonad-mesonephros) region,
leukocyte, 280–283, 282f, 282t protoporphyria, 899 54, 100f, 101, 257–258, 1149–1150
leukocyte–endothelial cell, 1977–1978, Afibrinogenemia/hypofibrinogenemia, Agranulocytosis, 991, 1097. See also
1977t 2154–2157 Neutropenia
monocytes and macrophages, 1059, 1060t clinical features, 2155 Agrin, 62

Kaushansky_index_p2393-2506.indd 2396 9/21/15 3:21 PM